IL111454A0 - Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals - Google Patents
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticalsInfo
- Publication number
- IL111454A0 IL111454A0 IL11145494A IL11145494A IL111454A0 IL 111454 A0 IL111454 A0 IL 111454A0 IL 11145494 A IL11145494 A IL 11145494A IL 11145494 A IL11145494 A IL 11145494A IL 111454 A0 IL111454 A0 IL 111454A0
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- pharmaceuticals
- substituted heterocyclic
- heterocyclic carboxamides
- carboxamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to compounds of the formula I <IMAGE> a process for their preparation, and their use as medicaments. In particular, the compounds are employed for the inhibition of collagen biosynthesis, as inhibitors of proline hydroxylase and as fibrosuppressants.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4337271A DE4337271A1 (en) | 1993-11-02 | 1993-11-02 | ubstd. heterocyclic carboxylic acid amides and their prepn. |
| DE19944410881 DE4410881A1 (en) | 1994-03-29 | 1994-03-29 | Substd. heterocyclic carboxylic acid amides and their prepn. |
| DE19944433928 DE4433928A1 (en) | 1994-09-23 | 1994-09-23 | Substd. heterocyclic carboxylic acid amides and their prepn. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL111454A0 true IL111454A0 (en) | 1994-12-29 |
| IL111454A IL111454A (en) | 2001-08-08 |
Family
ID=27205714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11145494A IL111454A (en) | 1993-11-02 | 1994-10-30 | Substituted heterocyclic carboxamides for use as pharmaceuticals, some such novel compounds and their preparation |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0650961B1 (en) |
| JP (1) | JPH07228571A (en) |
| KR (1) | KR950014072A (en) |
| CN (1) | CN1107145A (en) |
| AT (1) | ATE149486T1 (en) |
| AU (1) | AU676775B2 (en) |
| CA (1) | CA2134866A1 (en) |
| CY (1) | CY2120B1 (en) |
| CZ (1) | CZ289356B6 (en) |
| DE (1) | DE59401924D1 (en) |
| DK (1) | DK0650961T3 (en) |
| ES (1) | ES2101421T3 (en) |
| GR (1) | GR3023174T3 (en) |
| IL (1) | IL111454A (en) |
| MY (1) | MY112413A (en) |
| NO (1) | NO301880B1 (en) |
| NZ (1) | NZ264821A (en) |
| PL (1) | PL179794B1 (en) |
| TW (1) | TW399046B (en) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) * | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides |
| DE19746287A1 (en) * | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments |
| FR2803592A1 (en) * | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | NOVEL DERIVATIVES OF 3-HYDROXYPICOLINIC ACID, PROCESS FOR THEIR PREPARATION AND FUNGICIDAL COMPOSITIONS CONTAINING SAME |
| DE10123587B4 (en) * | 2001-05-08 | 2005-04-07 | Schering Ag | Cyanoanthranylamide derivatives and their use as pharmaceuticals |
| DE10123573B4 (en) * | 2001-05-08 | 2005-06-02 | Schering Ag | N-Oxidanthranylamide derivatives and their use as pharmaceuticals |
| EP1387838B1 (en) | 2001-05-08 | 2006-04-19 | Schering Aktiengesellschaft | Cyanoanthranilamide derivatives and the use thereof as medicaments |
| EP2295060B1 (en) | 2001-12-06 | 2018-10-31 | Fibrogen, Inc. | Treatment or prevention of ischemic or hypoxic conditions |
| EP1463823B1 (en) | 2001-12-06 | 2013-03-06 | Fibrogen, Inc. | Methods of increasing endogenous erythropoietin (epo) |
| CN101664409A (en) * | 2001-12-06 | 2010-03-10 | 法布罗根股份有限公司 | Stabilization of hypoxia inducible factor (HIF) alpha |
| US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| DK1644336T3 (en) * | 2003-06-06 | 2011-05-09 | Fibrogen Inc | Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| CN101166745A (en) | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | Novel thienopyridine compounds, and methods of use thereof |
| AU2006254897A1 (en) * | 2005-06-06 | 2006-12-14 | Fibrogen, Inc. | Improved treatment for anemia using a HIF-alpha stabilising agent |
| KR20080028918A (en) | 2005-06-15 | 2008-04-02 | 피브로겐, 인크. | Compounds and Methods for the Treatment of Cancer |
| CN102351791B (en) | 2006-01-27 | 2014-10-29 | 菲布罗根有限公司 | Cyanoisoquinoline compounds capable of making hypoxia inducible factor (HIF) stable |
| EP3124489B1 (en) | 2006-04-04 | 2020-07-15 | Fibrogen, Inc. | Thiazolo-pyridine compounds as hif modulators |
| LT3357911T (en) | 2006-06-26 | 2022-08-10 | Akebia Therapeutics Inc. | Prolyl hydroxylase inhibitors and methods of use |
| WO2009002533A1 (en) | 2007-06-27 | 2008-12-31 | The Brigham And Women's Hospital, Inc. | Inflammatory bowel disease therapies |
| US8080542B2 (en) * | 2007-09-20 | 2011-12-20 | Amgen, Inc. | S1P receptor modulating compounds and use thereof |
| NZ592741A (en) | 2008-11-14 | 2013-03-28 | Fibrogen Inc | Thiochromene derivatives as hif hydroxylase inhibitors |
| KR101007674B1 (en) * | 2010-08-13 | 2011-01-13 | 김병두 | High speed spray gun and coating device with auxiliary cap |
| KR101007675B1 (en) * | 2010-08-13 | 2011-01-13 | 김병두 | Plasma spray gun with auxiliary cap and plasma spray system using the same |
| NO2686520T3 (en) | 2011-06-06 | 2018-03-17 | ||
| JP6129217B2 (en) | 2012-03-09 | 2017-05-17 | フィブロジェン インコーポレイテッド | 4-Hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors |
| HUE037765T2 (en) | 2012-07-04 | 2018-09-28 | Agro Kanesho Co Ltd | 2-aminonicotinic acid ester derivative and bactericide containing same as active ingredient |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| CA2879238C (en) | 2012-07-16 | 2021-08-10 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| SMT202200095T1 (en) | 2012-07-16 | 2022-03-21 | Fibrogen Inc | Crystalline forms of a prolyl hydroxylase inhibitor |
| AU2014209319B2 (en) | 2013-01-24 | 2018-04-19 | Fibrogen, Inc. | Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid |
| SI3003284T1 (en) | 2013-06-06 | 2020-08-31 | Fibrogen, Inc. | Pharmaceutical formulations of a hif hydroxylase inhibitor |
| SG11201509998WA (en) | 2013-06-13 | 2016-01-28 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| RU2021125455A (en) | 2013-11-15 | 2021-10-05 | Экебиа Терапьютикс, Инк. | SOLID FORMS {[5- (3-CHLOROPHENYL) -3-HYDROXYPIRIDINE-2-CARBONYL] AMINO} ACETIC ACID, THEIR COMPOSITIONS AND APPLICATIONS |
| BR112017015852A2 (en) | 2015-01-23 | 2018-03-27 | Akebia Therapeutics Inc | crystal form, hemichalic salt, hemicalic salt dihydrate, hydrous monosodium salt, monohydrate bisodium salt, anhydrous monosodium salt and method for preparing compound 1 |
| CN106146395B (en) * | 2015-03-27 | 2019-01-01 | 沈阳三生制药有限责任公司 | 3- hydroxypyridine compound, preparation method and its pharmaceutical applications |
| TWI794725B (en) | 2015-04-01 | 2023-03-01 | 美商阿克比治療有限公司 | Compositions and methods for treating anemia |
| EP3790863A1 (en) | 2018-05-09 | 2021-03-17 | Akebia Therapeutics Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| DK3808747T3 (en) * | 2018-09-13 | 2025-02-03 | Kissei Pharmaceutical | Imidazopyridinone compound |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4015255A1 (en) | 1990-05-12 | 1991-11-14 | Hoechst Ag | OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE |
| EP0541042A1 (en) * | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | 2,4- and 2,5-pyridine-dicarboxylic acid derivatives, process for their preparation and their use |
| BR9306058A (en) * | 1992-03-11 | 1997-11-18 | Narhex Ltd | Amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
-
1994
- 1994-10-27 AT AT94117018T patent/ATE149486T1/en not_active IP Right Cessation
- 1994-10-27 EP EP94117018A patent/EP0650961B1/en not_active Expired - Lifetime
- 1994-10-27 DE DE59401924T patent/DE59401924D1/en not_active Expired - Fee Related
- 1994-10-27 DK DK94117018.5T patent/DK0650961T3/en active
- 1994-10-27 ES ES94117018T patent/ES2101421T3/en not_active Expired - Lifetime
- 1994-10-28 PL PL94305646A patent/PL179794B1/en unknown
- 1994-10-30 IL IL11145494A patent/IL111454A/en not_active IP Right Cessation
- 1994-10-31 MY MYPI94002894A patent/MY112413A/en unknown
- 1994-10-31 AU AU77564/94A patent/AU676775B2/en not_active Ceased
- 1994-10-31 NZ NZ264821A patent/NZ264821A/en unknown
- 1994-11-01 CZ CZ19942683A patent/CZ289356B6/en not_active IP Right Cessation
- 1994-11-01 CA CA002134866A patent/CA2134866A1/en not_active Abandoned
- 1994-11-01 NO NO944162A patent/NO301880B1/en not_active IP Right Cessation
- 1994-11-02 KR KR1019940028871A patent/KR950014072A/en not_active Ceased
- 1994-11-02 JP JP6292032A patent/JPH07228571A/en not_active Abandoned
- 1994-11-02 CN CN94117623A patent/CN1107145A/en active Pending
- 1994-12-05 TW TW083111257A patent/TW399046B/en not_active IP Right Cessation
-
1997
- 1997-04-18 GR GR970400831T patent/GR3023174T3/en unknown
-
1998
- 1998-09-29 CY CY9800039A patent/CY2120B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU7756494A (en) | 1995-05-18 |
| NZ264821A (en) | 1997-02-24 |
| CY2120B1 (en) | 2002-04-26 |
| EP0650961B1 (en) | 1997-03-05 |
| TW399046B (en) | 2000-07-21 |
| PL305646A1 (en) | 1995-05-15 |
| CA2134866A1 (en) | 1995-05-03 |
| PL179794B1 (en) | 2000-10-31 |
| ATE149486T1 (en) | 1997-03-15 |
| HK1006711A1 (en) | 1999-03-12 |
| KR950014072A (en) | 1995-06-15 |
| JPH07228571A (en) | 1995-08-29 |
| DE59401924D1 (en) | 1997-04-10 |
| MY112413A (en) | 2001-06-30 |
| DK0650961T3 (en) | 1997-09-15 |
| GR3023174T3 (en) | 1997-07-30 |
| CZ289356B6 (en) | 2002-01-16 |
| NO944162L (en) | 1995-05-03 |
| IL111454A (en) | 2001-08-08 |
| AU676775B2 (en) | 1997-03-20 |
| CN1107145A (en) | 1995-08-23 |
| NO944162D0 (en) | 1994-11-01 |
| ES2101421T3 (en) | 1997-07-01 |
| CZ268394A3 (en) | 1995-05-17 |
| NO301880B1 (en) | 1997-12-22 |
| EP0650961A1 (en) | 1995-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL111454A0 (en) | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | |
| PH31264A (en) | Substituted heterocyclic carboxamide esters, and their use as pharmaceuticals. | |
| AU697015B2 (en) | Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals | |
| IL116122A0 (en) | Intermediates to heterocyclic-cyclic amine derivatives | |
| AP9801237A0 (en) | Quinoline derivatives. | |
| DK0632026T3 (en) | Alpha-amino acid derivatives, a process for their preparation, and pharmaceutical compositions containing them | |
| AU6991696A (en) | 3-beta-aminoazabicyclo-octane or -nonane naphthamide derivatives as antipsychotic agents | |
| WO1995022544A3 (en) | Substituted 1,3,8-triaza-spiro(4,5)-decan-4-one derivatives useful as preliminary stages in the production of pharmaceuticals | |
| HU9400108D0 (en) | Salts of 4-pyrimidinone derivatives, process for producing them, and pharmaceuticals compositions contaning them | |
| MY112414A (en) | Substituted heterocyclic carboxamide esters, their preparation and their use as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |